Disclosures for "A 20-Week Multicenter, Randomized, Double-Blind (DB), Placebo-Controlled, Phase 3 Trial (EPX 100-003) of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in patients with Lennox-Gastaut Syndrome (LGS)"
-
Dr. Ray has received personal compensation for serving as an employee of Harmony Biosciences. Dr. Ray has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Harmony Biosciences.
-
Dr. Nomikos has received personal compensation for serving as an employee of Harmony Biosciences.
-
Mr. Runyan has received personal compensation for serving as an employee of Harmony Biosciences. Mr. Runyan has stock in Harmony Biosciences.
-
Mrs. Philip has nothing to disclose.
-
Dr. Albers has received personal compensation for serving as an employee of Harmony Biosciences. Dr. Albers has stock in Harmony Biosciences.
-
Prof. Baraban has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Harmony Biosciences.
-
Kumar Budur, MD has received personal compensation for serving as an employee of Harmony Biosciences. Kumar Budur, MD has stock in Abbvie.